Faïza Ajana

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Jean van Wyk, Faïza Ajana, Fiona Bisshop et al. · Clinical Infectious Diseases · 2020 · 257 citations · Full text

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Hans Jaeger, Edgar T. Overton, Gary Richmond et al. · The Lancet HIV · 2021 · 130 citations

Phase 3B, Treatment And Prevention, Clinical Epidemiology +10

Is Intrapartum Intravenous Zidovudine for Prevention of Mother-to-Child HIV-1 Transmission Still Useful in the Combination Antiretroviral Therapy Era?

Nelly Briand, Josiane Warszawski, Laurent Mandelbrot et al. · Clinical Infectious Diseases · 2013 · 126 citations · Full text

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial

Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana et al. · Clinical Infectious Diseases · 2022 · 123 citations · Full text

Newer drugs and earlier treatment

Caroline E. Sloan, Karen Champenois, P. Choisy et al. · AIDS · 2011 · 86 citations · Full text